ALLIED CORP - ALID STOCK NEWS

Allied Corp (OTCQB: ALID) has received import approval certificates for Australia and Peru, allowing the company to ship CBD products within the next 7 business days. These approvals represent significant milestones, enhancing Allied's market reach, which includes opportunities in the United States, Brazil, Canada, and other countries. The company meets regulatory compliance through adherence to European Pharmacopeia standards. CEO Calum Hughes emphasized the importance of quality assurance in driving business success.

Allied Corp (OTCQB: ALID) has achieved a significant milestone by completing its first commercial shipment of CBD from Colombia to the United States. This shipment, containing less than 0.3% THC, illustrates the company's robust supply chain capabilities, which span from seed production in Colombia to retail-ready products in the US. Allied's operations are sanctioned by various Colombian ministries, ensuring compliance with legal requirements. CEO Calum Hughes emphasized the importance of this achievement for future international market expansion.

Allied Corp (OTCQB: ALID) announces a supply and manufacturing agreement with HAVN Life Sciences to produce Psilonex™ RX psilocybin products. Under provisional patent, Psilonex™ RX will cater to over 300 veterans and emergency personnel seeking treatment for post-traumatic symptoms. The product will be dispensed under physician supervision, pending regulatory compliance. CEO Calum Hughes emphasizes the significance of this venture for the medical market addressing depression and anxiety. Allied is positioned as a leader in innovative mental health solutions.

Allied Corp (OTCQB: ALID), a medical company focused on mental health solutions, has signed an engagement agreement with Boustead Securities LLC for corporate financing and potential securities offerings. This partnership aims to support Allied’s goal of up-listing to the NASDAQ. The agreement follows the filing of Allied’s 1-A registration document on June 11, 2021. CEO Calum Hughes emphasized the importance of Boustead’s experience in aiding companies to achieve similar objectives, reinforcing Allied's strategy in the competitive medical cannabis space.

Allied Corp. (OTCQB: ALID) has launched an expansion of its Bucaramanga, Colombia facility, initiating the construction of 200,000 square feet of outdoor cultivation space. This upgrade will enhance its mothering, cloning, and vegetative infrastructure, facilitating a planned expansion to 49 acres by the end of 2021. The facility aims to increase its plant inventory capacity to meet rising international demand for cannabis derivatives. CEO Calum Hughes emphasizes that this development positions Allied for consistent supply and scale in the market.

Allied Corp (OTCQB: ALID) has achieved a significant milestone, harvesting 980 grams of dried cannabis per plant in its latest operation, up from a previous high of 905 grams. This increase reflects a strong production trend, with earlier harvests yielding 424 to 894 grams. Approximately 2,000 kilograms of cannabis flower is being processed for sale. Allied aims for a consistent supply by increasing its vegetative plant inventory to replace 9,000 plants expected to be harvested soon. CEO Calum Hughes highlights this progress as a step toward long-term market stability.

Allied Corp (OTCQB: ALID) announced the successful sell-out of its first harvest production inventory, reflecting strong demand for its products. The company has signed a purchase order from an international buyer, marking the completion of its initial harvest sales. Allied is expanding its production capabilities in Colombia, leveraging the region's favorable climate with a weekly rolling harvest schedule to ensure a reliable supply. With further export approvals, Allied is poised to meet national level quantities for wholesale buyers in international markets.

Allied Corp (OTCQB: ALID) has launched an e-commerce portal for its CBD products in the U.S. The portal showcases three brand lines: Tactical Relief™, Equilibrium Bio™, and MaXXa™, covering wellness, athletic, and beauty products respectively. Allied is also pursuing multi-state distributor contracts for retail presence. CEO Calum Hughes emphasized that building a brand and sales relationships is critical as the U.S. moves toward cannabis legalization. This marks a significant step for the company's growth strategy in the medical cannabis space.

Allied Corp (OTCQB: ALID) announced it received clearance from Colombian authorities to export cannabis-based products to a second international market, enhancing its sales reach. This follows earlier approval to export to its first market, marking a significant milestone since acquiring licenses in Colombia in February 2020. The company has developed a production center, registered its genetics, and secured sales contracts with international buyers. Approximately 650 companies are licensed to produce cannabis derivatives in Colombia, but only a few have export clearance.